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BACKGROUND AND OBJECTIVE
Venous thromboembolism (VTE) which comprises pulmonary embolism (PE) and deep
vein thrombosis (DVT) has been a public health concern for several years. VTE
accounts for an estimated 60,000 to 100,000 deaths per year in the United
States. Specifically, patients who present with an acute PE, it has been estimated 25%
of these patients have sudden death as the first symptom.2
Clinical presentation of an acute PE can manifest as nonspecific symptoms which may
include: chest pain, cough, hemoptysis, dyspnea, tachypnea, shortness of breath,
wheeze, and some patients may present in cardiopulmonary arrest.1,2 Severe acute PE
can be classified as either massive or submassive PE. A patient with a massive PE
would present with signs and symptoms of shock and persistent arterial
hypotension. Patients with submassive PE present with hemodynamic stability but
positive biomarkers (troponin and BNP) and right ventricular dysfunction.3 Patients
who present with PE are at higher risk of death and adverse outcomes with increasing
severity of illness and thrombolytic therapy is indicated in massive PE and may be
frequently utilized in submassive PE. Prior studies have identified APACHE II score and
need for mechanical ventilation as predictors of mortality in ICU patients, while
thrombolytic therapy was identified as protective, however, the urgency of
thrombolytic therapy administration has not been evaluated in severely ill
patients.5 The purpose of this study is to evaluate if time to thrombolytic therapy can
be used as a predictor of mortality in patients receiving intravenous thrombolysis for
severe acute PE.

DESIGN AND METHODS
Data Collection
• This study was a retrospective chart review of patients receiving intravenous
alteplase for PE from March 2013 through August 2017.
• Patients who received intravenous alteplase for PE per a standard order set were
identified from a database that underlies the electronic medical record (EMR).

DISCUSSION AND LIMITATIONS

RESULTS
Table 1: Baseline characteristics (n=43)

n (%)

Mean age, years
Female
Mean weight, kg
Admitted from emergency department
Classified as massive PE

61.8
23 (53.5)
100.6
33 (76.7)

Received 100 mg alteplase

42 (97.7)

History of tobacco use

21 (48.8)

History of hypertension

24 (55.8)

Anticoagulation before alteplase

29 (67.4)

29 (67.4)

Table 2: Univariate analysis of predictors of death.
Measure
Survivors N= 28 Non-survivors N = 15
P-value
Baseline Scr (mg/dL)
1.36
1.83
<0.01
Median sPESI score
2
3
0.025
RVSP (mmHg)
50
61.5
<0.01
BNP (pg/mL)
40,20
22,769
0.04
Time to alteplase (hours)
94
139
≥0.05
Classification of PE
Mortality Rate (%)
Massive
15
14
46.4%
Submassive
12
1
6.7%
*Scr = serum creatinine, sPESI = simplified PE severity index, RVSP = right ventricular
systolic pressure.
Figure 1: Box and whisker plot of time to alteplase between survivors and nonsurvivors.

• Data regarding risk factors for mortality in this patient population, including
laboratory findings, vital signs and co-morbid conditions, were manually extracted
from the EMR.

CONCLUSION
Time-to-alteplase administration was not a risk factor for mortality in our patient
population; however, the population may have been too small to detect clinically
meaningful differences. Larger studies should consider time from symptom onset to
alteplase administration and time from presentation to administration as potential
predictors for mortality. Future studies could evaluate more patient specific risk
factors, symptom presentation and laboratory values as well as different alteplase
dosing for predictors of death in patients with acute PE.
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Statistical Analysis
• Mann Whitney U test was used for analyzing differences in survivors and
nonsurvivors.
• Chi Sqare test was used for nominal risk factors for mortality.
• The Student T-test was used for continuous variables.
• If time-to-alteplase was found to be an independent predictor of mortality in
univariate analysis, a multivariate linear regression analysis would be conducted to
evaluate an association with mortality.

AUTHOR DISCLOSURES

Definition
• Time to alteplase was defined as the time from ER admission to onset of drug
administration, in minutes.

Discussion
• Alteplase is an effective treatment option for patients presenting with acute
massive PE but increases risk of major bleeding events and death from
complications.
• Severity of symptoms at presentation increase a patients risk for death.4 Few
studies have examined how time to alteplase administration in acute PE affects a
patient’s risk for death.
• Patients with massive PE were at higher risk of death than patients with
submassive PE.
• Out of 43 patients our study found no difference between time to administration
of alteplase and mortality in patients diagnosed with massive PE.
• No direct predictors of death were identified in patients who had multiple
comorbidities, a history of smoking and coagulopathy.
• Higher baseline serum creatinine, sPESI score, and RSVP were statistically
significant for predicting death in patients. (p <0.01, p = 0.025, & p<0.01
respectively). These identified risk factors for death were more likely indicative of
illness severity rather than specific risk factors related to alteplase administration.
Limitations
• Single site and small sample size, n=43.
• Hospital admitted patients that developed a PE may skew the results.
• BNP values was found to be a statistically significant biomarker but only 17 of 43
patients had BNP measured.

• Outliers > 30 hours have been removed, however, this does not change the outcome of figure 1.
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• Alteplase can be an effective treatment option for patients presenting with acute
ischemic stroke, but there has been significant controversy over its safety and
efficacy after a prolonged period of time has passed from onset of symptoms4.
• Saver, et al published a trial in 2013 examining the time to treatment with
intravenous tissue plasminogen activator and resulting outcomes. Through this
large retrospective trial of nearly 58,000 patients, a faster administration
of treatment was associated with decreased mortality, reduced symptomatic
intracranial hemorrhage, increased independent ambulation at discharge and
increased discharge to home rate5.
• No difference was found between time to administration of alteplase and
mortality. This is limited by the number of available patients receiving the
treatment medication, as well as the single site collection. This may also be limited
by those patients who experienced prolonged asymptomatic periods prior to
administration of alteplase. Health care contact may have been made, but there is
a potential for the PE to be undetected. Only upon a later rapid decompensation of
the patient was a PE suspected. There were a large portion of patients who had
multiple comorbidities, smoking history, as well as an excessive weight that
resulted in PE, but were not direct predictors of death.
• By identifying potential risk factors for mortality associated with PE, health care
providers in the acute and critical care settings can provide a higher level of care by
anticipating potential needs and appropriately utilizing available treatment
options.
This study was a retrospective chart review of patients receiving intravenous alteplase for PE
from March 2013 through August 2017.
• Patients who received intravenous alteplase for PE per a standard order set were
identified from a database that underlies the electronic medical record (EMR).
• Data regarding risk factors for mortality in this patient population, including laboratory
findings, vital signs and co-morbid conditions, were manually extracted from the EMR.
Differences in characteristics were compared between hospital survivors and nonsurvivors.
• Time to alteplase was defined as the time from ER admission to onset of drug
administration, in minutes.
• Differences between survivors and non-survivors were compared using the MannWhitney U test.
• Nominal risk factors for mortality were compared using the chi square test while other
continuous variables were compared using the student t-test.
• If time-to-alteplase was found to be an independent predictor of mortality in univariate
analysis, a multivariate linear regression analysis would be conducted to evaluate an
association with mortality.

Time-to-alteplase administration was not associated with mortality in our patient
population; however, the population may have been too small to detect clinically
meaningful differences. Patients with massive PE were at higher risk of death than
patients with submassive PE and other identified risk factors for death were more
likely indicative of illness severity rather than specific risk factors related to alteplase
administration. Larger studies should consider time from symptom onset to alteplase
administration and time for presentation to administration as potential predictors for
mortality.

